テルミサルタンの選択的PPARγ活性化作用と期待される心保護作用

文献

J-GLOBAL ID：200902253910011372 整理番号：07A0934319

出版者サイト {{ this.onShowPLink() }} 複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=07A0934319&COPY=1") }}
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=07A0934319&from=J-GLOBAL&jstjournalNo=F0692A") }}

著者 (1件)：
資料名：
巻： 39 号： 11 ページ： 474-477 発行年： 2007年10月20日
JST資料番号： F0692A ISSN： 1346-7557 資料種別：逐次刊行物 (A)
記事区分：解説発行国：日本 (JPN) 言語：日本語 (JA)

テルミサルタンはARBとしてのAT₁受...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=07A0934319&from=J-GLOBAL&jstjournalNo=F0692A") }}

循環系作用薬一般

引用文献 (10件)：

Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-235, 2005.
Lacourcicre Y, Krzesinski JM, White WB, et al.: Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 9: 203-210, 2004.
Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 43: 993-1002, 2004.
Araki K, Masaki T, Katsuragi I, Tanaka K. Kakuma T, Yoshimatsu H: Telmisartan prevents obesity and increases the expression of uncoupling protein I in dietinduced obese mice. Hypertension 48: 51-57, 2006.
Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y: Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 Diabetes. Metabolic and antiatherogenic consequences. Diabetes Care 28: 757-758, 2005.

, , , ,

前のページに戻る